KYVERNA THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
Portfolio Pulse from
Kahn Swick & Foti, LLC has issued a reminder to investors of Kyverna Therapeutics, Inc. about the lead plaintiff deadline for a class action lawsuit. The lawsuit concerns losses exceeding $100,000 related to the company's IPO in February 2024. Investors have until February 7, 2025, to file lead plaintiff applications.
December 13, 2024 | 3:00 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kyverna Therapeutics is facing a class action lawsuit related to its February 2024 IPO, with a lead plaintiff deadline set for February 7, 2025. The lawsuit is for investors with losses over $100,000.
The class action lawsuit against Kyverna Therapeutics is likely to negatively impact its stock price in the short term due to potential legal liabilities and investor concerns. The lawsuit pertains to significant financial losses related to the company's IPO, which could lead to decreased investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100